7,419 Shares in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Bought by SG Americas Securities LLC

SG Americas Securities LLC purchased a new stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 7,419 shares of the company’s stock, valued at approximately $297,000.

A number of other large investors have also recently bought and sold shares of the business. nVerses Capital LLC bought a new position in shares of Ionis Pharmaceuticals in the 2nd quarter worth $29,000. Mather Group LLC. acquired a new position in shares of Ionis Pharmaceuticals during the first quarter valued at about $29,000. Itau Unibanco Holding S.A. bought a new stake in shares of Ionis Pharmaceuticals during the second quarter worth about $37,000. Sunbelt Securities Inc. acquired a new stake in shares of Ionis Pharmaceuticals in the 1st quarter worth about $44,000. Finally, Advisors Asset Management Inc. lifted its position in Ionis Pharmaceuticals by 948.8% in the 1st quarter. Advisors Asset Management Inc. now owns 3,178 shares of the company’s stock valued at $138,000 after acquiring an additional 2,875 shares in the last quarter. 93.86% of the stock is currently owned by institutional investors and hedge funds.

Ionis Pharmaceuticals Stock Up 3.1 %

IONS opened at $39.68 on Friday. The company has a 50 day moving average of $43.23 and a 200 day moving average of $43.24. The company has a current ratio of 7.61, a quick ratio of 7.51 and a debt-to-equity ratio of 4.67. Ionis Pharmaceuticals, Inc. has a 12 month low of $35.95 and a 12 month high of $54.44. The company has a market cap of $5.79 billion, a PE ratio of -14.86 and a beta of 0.38.

Ionis Pharmaceuticals (NASDAQ:IONS) last announced its quarterly earnings results on Thursday, August 1st. The company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.47. Ionis Pharmaceuticals had a negative return on equity of 115.66% and a negative net margin of 44.90%. The firm had revenue of $225.00 million for the quarter, compared to analysts’ expectations of $152.35 million. During the same period in the prior year, the business posted $0.60 earnings per share. The company’s revenue was up 19.7% on a year-over-year basis. On average, sell-side analysts expect that Ionis Pharmaceuticals, Inc. will post -3.68 EPS for the current year.

Analysts Set New Price Targets

Several research firms have recently issued reports on IONS. JPMorgan Chase & Co. upped their target price on shares of Ionis Pharmaceuticals from $50.00 to $55.00 and gave the stock a “neutral” rating in a research note on Monday, August 26th. Royal Bank of Canada reiterated an “outperform” rating and issued a $70.00 price objective on shares of Ionis Pharmaceuticals in a research note on Thursday, September 26th. The Goldman Sachs Group boosted their target price on Ionis Pharmaceuticals from $33.00 to $37.00 and gave the stock a “sell” rating in a research note on Friday, August 2nd. Barclays increased their price target on Ionis Pharmaceuticals from $45.00 to $51.00 and gave the company an “equal weight” rating in a research report on Friday, August 2nd. Finally, BMO Capital Markets cut Ionis Pharmaceuticals from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $67.00 to $60.00 in a research report on Friday, August 2nd. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $60.28.

Insiders Place Their Bets

In other news, EVP Richard S. Geary sold 2,430 shares of the business’s stock in a transaction on Monday, August 5th. The shares were sold at an average price of $48.00, for a total transaction of $116,640.00. Following the completion of the transaction, the executive vice president now directly owns 85,508 shares in the company, valued at $4,104,384. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold 2,803 shares of company stock worth $134,402 in the last three months. 2.71% of the stock is currently owned by corporate insiders.

Ionis Pharmaceuticals Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.